ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer

Cancer Biology and Therapy

Volumn 8, Issue 14, 2009, Pages 112-118

  Chen, Jianfang ^a   Xie, Fangwei ^a   Chen, Keli ^a   Wang, Dong ^b   Jiang, Heng ^a   Li, Jianjun ^a   Pan, Feng ^a   Chen, Shixu ^a   Zhang, Yanling ^a   Ruan, Zhihua ^a   Huang, Haihui ^a   Zou, Lan ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; ERCC5; Oxaliplatin based chemotherapy; Polymorphism

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; OXALIPLATIN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC 5; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; NUCLEAR PROTEIN; PLATINUM COMPLEX; TRANSCRIPTION FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; ERCC5 GENE; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; AGED; CHINA; COLORECTAL TUMOR; DNA REPAIR; DRUG EFFECT; DRUG RESISTANCE; ETHNIC GROUP; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROMOTER REGION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHINA; COLORECTAL NEOPLASMS; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 68149164667     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:4006-14.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
3. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006; 95:131-8.
4. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23:4553-60.
5. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:4-12.
6. Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 1980; 30:151-69.
7. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91.
8. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87:772-7.
9. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61:8654-8.
10. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 2008; 18:64-72.
11. Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, Podust VN, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995; 80:859-68.
12. Dunand-Sauthier I, Hohl M, Thorel F, Jaquier-Gubler P, Clarkson SG, Scharer OD. The spacer region of XPG mediates recruitment to nucleotide excision repair complexes and determines substrate specificity. J Biol Chem 2005; 280:7030-7.
13. Hohl M, Dunand-Sauthier I, Staresincic L, Jaquier-Gubler P, Thorel F, Modesti M, et al. Domain swapping between FEN-1 and XPG defines regions in XPG that mediate nucleotide excision repair activity and substrate specificity. Nucleic Acids Res 2007; 35:3053-63.
14. O'Donovan A, Davies AA, Moggs JG, West SC, Wood RD. XPG endonuclease makes the 3′ incision in human DNA nucleotide excision repair. Nature 1994; 371:432-5.
15. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 2008:2952-8.
16. Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res 2004; 10:5604-13.
17. Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008; 7:10-8.
18. Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 2007; 72:364-70.
19. Wray GA, Hahn MW, Abouheif E, Balhoff JP, Pizer M, Rockman MV, et al. The evolution of transcriptional regulation in eukaryotes. Mol Biol Evol 2003; 20:1377-419.
20. Mohrenweiser H. Survey of polymorphic sequence variation in the immediate 5′ region of human DNA repair genes. Mutat Res 2007; 616:221-6.
21. Crawford EL, Blomquist T, Mullins DN, Yoon Y, Hernandez DR, Al-Bagdhadi M, et al. CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogenesis 2007; 28:2552-9.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
23. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12:3050-6.
24. Polavarapu N, Marino-Ramirez L, Landsman D, McDonald JF, Jordan IK. Evolutionary rates and patterns for human transcription factor binding sites derived from repetitive DNA. BMC Genomics 2008; 9:226.
25. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003; 31:374-8.
26. Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, et al. Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors. Oncogene 1999; 18:27-38.
27. Ding K, Zhou K, He F, Shen Y. LDA - a java-based linkage disequilibrium analyzer. Bioinformatics 2003; 19:2147-8.
28. Scheet P, Stephens M. A fast and flexible statistical model for large-scale population genotype data: Applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 2006; 78:629-44.
29. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91:344-54.
30. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25:1247-54.
31. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008; 99:1050-5.
32. Hudson TJ. Wanted: regulatory SNPs. Nat Genet 2003; 33:439-40.
33. Wang X, Tomso DJ, Liu X, Bell DA. Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 2005; 207:84-90.
34. Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O'Donovan MC. Strong bias in the location of functional promoter polymorphisms. Hum Mutat 2005; 26:214-23.
35. Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54:171-96.
36. Jeon HS, Kim KM, Park SH, Lee SY, Choi JE, Lee GY, et al. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis 2003; 24:1677-81.
37. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006; 27:560-7.
38. Chang JS, Wrensch MR, Hansen HM, Sison JD, Aldrich MC, Quesenberry CP, et al. Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. Int J Cancer 2008; 123:2095-104.
39. Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, Consortium TG, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 2007; 16:2333-40.
40. Rajaraman P, Bhatti P, Doody MM, Simon SL, Weinstock RM, Linet MS, et al. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer 2008; 123:2713-6.
41. Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 2003; 89:333-7.
42. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms in genes of nucleotide and base excision repair: Risk and prognosis of colorectal cancer. Clin Cancer Res 2006; 12:2101-8.
43. Huang WY, Berndt SI, Kang D, Chatterjee N, Chanock SJ, Yeager M, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiol Biomarkers Prev 2006; 15:306-11.
44. Bigler J, Ulrich CM, Kawashima T, Whitton J, Potter JD. DNA repair polymorphisms and risk of colorectal adenomatous or hyperplastic polyps. Cancer Epidemiol Biomarkers Prev 2005; 14:2501-8.